Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Mast Cell Disorders
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Related Questions
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
Are you requiring markers other than LTE4 to be elevated to diagnose MCAS?
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell disorders besides omalizumab?
What is the overlap of POTS and Ehlers-Danlos with MCAS?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Do mRNA vaccines lead to increased rates of acute/chronic urticaria?
Do you recommend avoiding all citrus seeds and fruits if a patient has demonstrated and IgE mediated allergy to a lemon seed?
